PerkinElmer and Massachusetts General Hospital Pathology Collaborate to Develop a Complete Sequencing Informatics System for Cancer Research
Global leader in life sciences to help leading research hospital advance innovation in cancer research
WALTHAM, Mass.--PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it has entered into a collaboration with Dr. John Iafrate and Dr. Long Le of the Massachusetts General Hospital (MGH) Pathology Department and Cancer Center to develop a sequencing informatics system for profiling the genetic changes in tumors for use in advanced cancer research.
Based on PerkinElmer's Geospiza® informatics platforms, the new system is expected to help guide the development of cancer treatments by enabling genotype analysis to define key genetic targets from which clinically relevant information can be leveraged. Under the terms of the agreement, PerkinElmer will develop a highly automated sample preparation and data analysis system suitable for cancer genotyping in clinical research at the MGH Pathology Department and Cancer Center. PerkinElmer's Geospiza GeneSifter® Laboratory and Analysis edition software platform will be enhanced with sophisticated variant detection algorithms. The new system will also integrate existing laboratory processes and equipment with enhanced LIMS and data analysis capabilities.
The informatics system will support the cancer research of Dr. Long Le and Dr. John Iafrate of the MGH Pathology Department and Cancer Center. "A key challenge presented by next generation sequencing applications in clinical research is not only maintaining high efficiency and throughput via automation solutions, but also ensuring that the informatics driving the instrumentation provides transparency and traceability for the entire process," said Dr. Le.
Kevin Hrusovsky, president of Life Sciences & Technology at PerkinElmer, said, "Working with the MGH Pathology Department and Cancer Center to support their critically important cancer research is a deeply rewarding collaboration and is consistent with our goal to help researchers eradicate this deadly disease. We are delighted to provide MGH with a complete next generation sequencing informatics and sample preparation solution to help advance their medical research."
The MGH Pathology Department and Cancer Center are currently using the high quality service and data from PerkinElmer's DNA Sequencing Services group and deploys PerkinElmer's Sciclone® automated liquid handling platform and the NGS Express™ Workstation for benchtop sequencers.
For more information on PerkinElmer's Geospiza informatics offering, please visit http://www.geospiza.com
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.9 billion in 2011, has about 7,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Contacts
Edelman (On behalf of PerkinElmer, Inc.)
Amanda Lazaro Connolly, 404-832‐6785
[email protected]